Prediction of locoregional extension and metastatic disease in prostate cancer: A review

World Journal of Urology

Volumn 18, Issue 3, 2000, Pages 165-172

  Reckwitz, Thomas ^a   Potter, Steven R ^a   Partin, Alan W ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

,staging; Neural network; Nomogram; Prostate cancer; Regression analysis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ALGORITHM; ARTIFICIAL NEURAL NETWORK; BLOOD; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FORECASTING; HUMAN; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROSTATE TUMOR; REGRESSION ANALYSIS; REVIEW;

ALGORITHMS; FORECASTING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEURAL NETWORKS (COMPUTER); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0034207784     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007073     Document Type: Article

References (43)

1. American Cancer Society (1999) Cancer facts and figures 1999. American Cancer Society, Atlanta, GA
2. Barnhill SD, Stamey TA, Zhang Z, Zhang H, Madyastha KR (1997) The ability of the ProstAsure index to identify prostate cancer patients with low cancer volumes and a high potential for cure. J Urol 157 [Suppl]: 63
3. Blackwell KL, Bostwick DG, Myers RP, Zincke H, Oesterling JE (1994) Combining prostate specific antigen with cancer and gland volume to predict more reliably pathologic stage: the influence of prostate specific antigen cancer density. J Urol 151 : 1565-1570
4. Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE (1994) Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 151: 1315-1320
5. Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan M, Scardino PT, Montie JE, Pearson JD, Slezak JM, Zincke H (1999) Validation of the Partin tables for predicting pathologic stage of clinically confined prostate cancer. J Urol 161 [Suppl]: 238
6. Carter HB, Partin AW, Luderer AA, Metter EJ, Landis P, Chan DW, Fozard JL, Pearson JD (1997) Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 49: 379-384
7. Carter HB, Epstein JI, Partin AW (1999) Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 53: 126 130
8. Catalona WJ. Partin AW, Chan DW, Tindall D.I. Young CYF. Klee GC, Darte C, Finlay JA, Riltenhouse AG. Wolfert RL. Woodrum DL (I999) Detection of prostate cancer with %fPSA and hK2 when PSA is 2-4 ng/ml. J Urol 161 [Suppl]: 207
9. Crawford ED, Snow P. Lynch J, McLeod D. Baluello J, Partin AW. Stock R, Stone N, Gamito E, Brandt J (1999) Artificial intelligence system in prediction of lymph node involvement in radical prostatectomy patients. J Urol. 161 [Suppl]: 236
10. Christensson A, Bjork T, Nilsson O. Dahlen U, Matikainen MT, Cockett AT, Abrahamsson PA. Lilja H (1993) Serum prostate specific antigen complexed to alpha 1-antiehymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105
11. Darson MF, Pacelli A, Röche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG (1997) Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49: 857-862
12. Douglas TH, Connelly RR. McLeod DG, Moul JW. Snow PB (1996) Neural network analysis of preoperative and postoperative variables to predict pathologic stage and recurrence following radical prostatectomy. J Urol 155 [Suppl]: 487A
13. Epstein JI, Chan DW, Sokoll LJ. Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB (1998) Nonpalpable stage Tic prostate cancer: prediction of insignificant disease using free; total prostate specific antigen levels and needle biopsy findings. J Urol 160: 2407-2411
14. Faraggi D, Simon R (1995) A neural network model for survival data. Stat Med 14: 73-82
15. Grignon DJ, Hammond EH (1995) College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. Arch Pathol Lab Med 119: 1122-1126
16. Harris MJ, Bishoff JT, Reyes A, Thompson IM (1994) Preoperative PSA and prostate biopsy Gleason's grade predictive of benign pelvic lymph nodes in men with prostate cancer. J Urol 151 [Suppl]: 451
17. Huncharek M, Muscat J (1996) Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer. Abdom Imaging 21: 364-367
18. Ikonen S, Karkkainen P, Kivisaari L, Salo JO, Taari K, Vehmas T, Tervahartiala P, Rannikko S (1998) Magnetic resonance imaging of clinically localized prostatic cancer. J Urol 159: 915-919
19. Kattan MW, Stapleton AMF, Wheeler TM, Scardino PT(1997) Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 79: 528-537
20. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM. Scardino PT (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766-771
21. Kattan MW. Witte M, Morton RA, Cangiano T. deKernion J. Eastham JA, Meyer F, Fradet Y (1999) Validation of a nomogram for predicting disease recurrence following radical prostatectomy for clinically localized prostate cancer. J Urol 161 [Suppl]: 329
22. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE (1993) Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology 41: 207-216
23. Kwiatkowski M, Recker R, Piironen T, Pettersson K, Lummen G, Huber A, Tscholl R (1999) Various ratios of human glandular kallikrein (hK2) to free and total PSA improve discrimination between G1-G2 and G3 prostate tumors. J Urol 161 [Suppl]: 239
24. Manyak MJ, Javitt MC (1998) The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. Semin Urol Oncol 16: 145-152
25. Movsas B, Hanlon AL, Teshima T, Hanks GE (1997) Analyzing predictive models following definitive radiotherapy for prostate carcinoma. Cancer 80: 1093-1102
26. Narayan P. Fournier G, Gajendran V. Leidich R, Lo R. Wolf JS. Jacob G, Nicolaisen G. Palmer K. Freiha F (1994) Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node métastases in prostate cancer. Urology 44: 519- 524
27. O'Dowd G.I. Veltri RW, Orozco R. Miller MC. Oesterling JE (1997) Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol 158: 687 698
28. Oesterling JE. Brendler CB, Epstein JI. Kimball AW Jr. Walsh PC (1987) Correlation of clinical stage, serum prostalic acid phosphatase and preoperative Gleason grade with (inal pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 138: 92 98
29. Pannek J. Partin AW (1998) The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Semin Urol Oncol 16: 100-105
30. Partin AW. Carter HB, Chan DW. Epstein JI, Oesterling JE, Rock RC, Weber JP. Walsh PC (1990) Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752
31. Partin AW, Pound CR. Clemens JQ, Epstein JI, Walsh PC (1993) Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 20: 713-725
32. Partin AW, Yoo J. Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114
33. Partin AW, Rattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update. JAMA 277: 1445-1451
34. Polascik TJ. Manyak MJ. Haseman MK. Gurganus RT, Rogers B, Maguire RT, Partin AW (1999) Comparison of clinical staging algorithms and '"indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 85: 1586-1592
35. Potter SR, Miller MC, Mangold LA, Jones KA, Epstein JI, Veltri RW, Partin AW (1999) Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 54: 791-795
36. Potter SR, Reckwitz T, Partin AW (1999) The use of percent free PSA for early detection of prostate cancer. J Andrology 20: 44953
37. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW (1998) Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related but distinct kallikreins in the prostate. Crit Rev Clin Lab Sei 35: 275-368
38. Snow PB, Smith DS, Catalona WJ (1994) Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol 152: 1923-1926
39. Spevack L, Killion LT, West JC, Rooker GM, Brewer EA, Cuddy PG (1996) Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models. Int J Radiât Oncol Biol Phys 34: 543-547
40. Tewari A, Narayan P (1998) Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks. J Urol 160: 430-436
41. Veltri RW et al (1999) UroScore performance characteristics, (in press)
42. Vijayakumar S, Karrison T. Weichselbaum RR, Chan S, Quadri SF, A wan AM (1992) Racial differences in prostatespecific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev 1: 541-545
43. Wolf JS, Cher M, Dall'Era M, Presti JC, Hricak H, Carroll PR (1995) The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastasis before radical prostatectomy. J Urol 153: 993-999